SecBot SecBot
8-K ·Filed Nov 4, 2026

OPK

OPKO HEALTH, INC.
NEUTRAL
Impact 6/10
Horizonmonths Processed12d 11h ago SEC0001193125-26-447357
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Labcorp sale transforms OPKO into a pure-play biopharma company, removing the loss-making diagnostics segment. Watch for regulatory approval timeline and closing conditions for the $722M deal, and whether the $125M royalty financing signals further capital needs or a bridge to closing.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

OPK drug pipeline →

OPK-8801001

● Neutral Named in this 8-K
Impact
Phase
Phase 1/2a
Time to market
At least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.
Next catalyst
None dated

What to watchOPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.75
T+0 close · Nov 4, 2026 · via day close
Latest settled
−4.57%
T+5 · $1.67 · next T+20 in 17d
Vs SPY
−7.86%
α at T+5
Latest observation
−3.73%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $1.75entry
  2. T+1 · 11d ago −1.14%α −1.46% · $1.73
  3. T+5 · 5d ago −4.57%α −7.86% · $1.67
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included discontinued diagnostics revenue now reclassified. Net loss from continuing operations was $35.5M ($0.05 per share), versus consensus EPS of -$0.06. The headline event is the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M in cash at closing plus up to $150M in contingent consideration, and a $125M senior secured royalty financing with HealthCare Royalty.

Key Financial Metrics

EPS
−$0.05
est −$0.06 · +16.7%
Revenue
$65.4M
est $136.6M · -52.1% · +16.0% YoY
Rating
in line
Guidance
$62M-$72M (Q4 2026 continuing ops)
withdrawn

Key Facts

  • Agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M cash at closing plus up to $150M contingent on 4Kscore sales
  • Issued $125M additional senior secured royalty notes to HealthCare Royalty, secured by mazdutide royalty payments from Eli Lilly
  • Continuing operations revenue $65.4M (+16% YoY), above consensus of $136.6M which included discontinued diagnostics
  • Net loss from continuing operations $35.5M ($0.05 per share) vs consensus EPS -$0.06
  • Withdrew previously issued guidance for services revenue and total costs and expenses due to pending Labcorp transaction
  • Cash, cash equivalents and restricted cash $403.2M as of September 30, 2026
  • Repurchased 7,050,000 shares for $10.6M during Q3; $84.3M remaining under $200M buyback authorization

Financial Impact

Sale of BioReference for $722M cash plus up to $150M contingent; $125M additional royalty financing; continuing operations revenue $65.4M

revenueepsdebtdilution

Segment Breakdown

SegmentRevenueGrowth
Global Products$48.4M+22.8%
Innovative Biotech$17.0M0.0%

Risk Factors

  • Labcorp transaction subject to regulatory approvals and customary closing conditions; may not close or may be delayed
  • Withdrawn guidance creates near-term uncertainty for revenue and cost forecasts
  • Discontinued operations generated a $18.0M loss in Q3 2026, and are guided to lose $35M-$45M in Q4 2026
  • Senior secured royalty financing increased to $370.2M, adding leverage

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-447357
Document: opk-20261104.htm0001193125-26-447357
Document: 0001193125-26-447357-index-headers.html0001193125-26-447357
Document: 0001193125-26-447357-index.html0001193125-26-447357
Document: 0001193125-26-447357.txt0001193125-26-447357
8-K Data (Synthetic)0001193125-26-447357

US Market Status

Market Closed · Opens in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026